Related Experiment Videos
From HER2 to herceptin
1St George's Hospital, Blackshaw Road, London SW17 0QT, UK. kefahmokbel@hotmail.com
Current Medical Research and Opinion
|July 24, 2001
Summary
HER2 overexpression in breast cancer impacts prognosis and treatment response. Trastuzumab (Herceptin) offers a targeted therapy option with a favorable safety profile for HER2-positive metastatic breast cancer.
Area of Science:
- Oncology
- Pharmacology
Background:
- HER2 overexpression is present in 25% of breast cancers, associated with poor prognosis.
- HER2 status influences response to chemotherapy and hormonal therapies like tamoxifen.
Purpose of the Study:
- To evaluate the efficacy and safety of Trastuzumab (Herceptin) for HER2-overexpressing metastatic breast cancer.
- To assess Trastuzumab's role as a single agent and in combination therapy.
Main Methods:
- Pre-clinical studies in mice using monoclonal antibodies.
- Phase II and III clinical trials in women with metastatic breast cancer.
Main Results:
- Trastuzumab is effective as a single agent and in combination with paclitaxel for HER2-positive metastatic breast cancer.
- Herceptin is well-tolerated, with fewer common chemotherapy side effects.
- Cardiotoxicity risk is linked to prior anthracycline exposure.
Conclusions:
- Trastuzumab is a valuable targeted therapy for HER2-overexpressing metastatic breast cancer.
- The drug demonstrates a manageable safety profile, particularly regarding cardiotoxicity.
- Ongoing research is exploring Trastuzumab's use in the adjuvant setting.